Prescribers are now required to offer naloxone hydrochloride, or another drug approved by the Food and Drug Administration, to patients who experience certain conditions related to opioid depression. The Medical Board of California has released frequently asked questions to assist providers in implementing the new requirements, which took effect Jan. 1.
No Surprises Act Rule Released, Requires Health Plans to Report Prescription Drug and Health Care Spending DataCHA News
For CEOs, CFOs, government relations executives, finance & reimbursement staff, legal counselDetails
For CMO, CNOs, COOs, pharmacy staffDetails
For behavioral health CEOs & directors, compliance staffDetails